

9.1 Composition of Parenteral Nutrition: Branched Chain Amino Acids (BCAA)

June 28th, 2005

Recommendation:

In patients receiving parenteral nutrition, there are insufficient data to make a recommendation regarding the use of branched chain amino acids in critically ill patients.

Discussion: The committee noted the modest treatment effect for mortality with wide confidence intervals. The committee was concerned about the heterogeneity of findings in these 5 studies (test for heterogeneity $p = 0.16$) only one study demonstrating a statistically significant reduction in mortality (Garcia De Lorenzo). Safety was not considered to be a great concern however feasibility and cost were unfavourable.

Values	definition	Score: 0, +, ++, +++
Effect size	magnitude of the absolute risk reduction attributable to the intervention listed--a higher score indicates a larger effect size	2+ (mortality)
Confidence interval	95% confidence interval around the point estimate of the absolute risk reduction, or the pooled estimate (if more than one trial)--a higher score indicates a smaller confidence interval	2+
Validity	refers to internal validity of the study (or studies) as measured by the presence of concealed randomization, blinded outcome adjudication, an intention to treat analysis, and an explicit definition of outcomes--a higher score indicates presence of more of these features in the trials appraised	2+
Homogeneity	similar direction of findings among trials--a higher score indicates greater similarity of direction of findings among trials	1+
Safe	estimated probability of avoiding any significant harm that may be associated with the intervention listed--a higher score indicates a lower probability of harm	2+
Feasible	ease of implementing the intervention listed--a higher score indicates greater ease of implementing the intervention in an average ICU	1+
Cost	estimated cost of implementing the intervention listed--a higher score indicates a lower cost to implement the intervention in an average ICU	1+

9.1 Topic: Composition of Parenteral Nutrition: Branched Chain Amino Acids (BCAA)

June 28th, 2005

Question: Do BCAA in parenteral nutrition affect outcomes in the critically ill adult patient?

Summary of evidence: There were 5 level 2 studies reviewed.

Mortality: There were 4 studies that reported on mortality, 3 of these found no significant difference in mortality between the groups receiving higher amounts of BCAA and lower amounts (von Meyenfeldt, Vanway, Kuhl). Only one study found a significant reduction in mortality ($p < 0.03$) in septic patients receiving 45 % BCAA vs lower (standard) amounts (Garcia de-Lorenzo). Meta-analysis of these studies showed a trend towards a reduction in mortality in the groups receiving BCAA (RR 0.58, 0.26-1.28, $p = 0.18$ See figure page 9.1-5).

Infections: Two studies reported on infections and found no differences in infections with the use of BCAA (Ott et al ($p=0.68$), Kuhl et al.

LOS and Ventilator days: Only one study (Garcia de-Lorenzo) reported on LOS but there were no differences between groups.

Other complications: Not reported.

Conclusions:

- 1) Higher levels of BCAA are associated with a trend towards a reduction in mortality, when compared to standard amounts of BCAA.
- 2) No differences found in infections, LOS or ventilated days between groups receiving higher and standard amounts of BCAA.

Level 1 study: if all of the following are fulfilled: concealed randomization, blinded outcome adjudication and an intention to treat analysis.

Level 2 study: If any one of the above characteristics are unfulfilled.

Table 1. Randomized studies evaluating BCAA (PN) in critically ill patients

Study	Population	Methods (score)	Intervention	Mortality # (%)		Infections # (%)‡	
				BCAA	Standard	BCAA	Standard
1) Ott 1988	Brain injured patients N = 20	C.Random: not sure ITT: yes Blinding: no (6)	BCAA (Aminosyn) vs standard PN (travasol)	BCAA NA	Standard NA	BCAA 4/10 (40)	Standard 4/10 (40)
2) Von Meyenfeldt 1990	Septic and traumatized patients N = 101	C.Random: not sure ITT: yes Blinding: double (10)	50 % BCAA vs 16 % BCAA (standard)	BCAA 17/49 (35) hospital	Standard 16/52 (31) hospital	BCAA NA	Standard NA
3) Van Way 1995	Mixed surgical population, severely stressed N = 12	C.Random: not sure ITT: yes Blinding: no (7)	45 % BCAA vs 25 % BCAA (standard)	BCAA 1/6 (17) hospital	Standard 4/6 (67) hospital	BCAA NA	Standard NA
4) Garcia De Lorenzo 1997	Septic ICU patients N = 69	C.Random: not sure ITT: yes Blinding: no (8)	3 groups: (A) standard BCAA + 1.5 g/kg/day AA (B) 45 % BCAA + 1.5 g/kg/day AA (C) 45 % BCAA + 1.1 g/kg/day AA Compared (B) + (C) TO (A)	(A) 9/22 (41) 10/22 (46)	(B) ICU Hospital 2/25 (8) 2/25 (8)	(C) 5/22 (23) 6/22 (27)	NA NA
5) Kuhl 1990	Trauma patients requiring PN N = 20	C.Random: not sure ITT: yes Blinding: no (8)	46 % BCAA vs. 21 % BCAA (standard)	BCAA 1/10 (10)	Standard 2/10 (20)	BCAA 9/10 (90)	Standard 9/10 (90)


Table 1 (continued). Randomized studies evaluating BCAA (PN) in critically ill patients

Study	LOS days		Ventilator days		Cost		Other	
	BCAA	Standard	BCAA	Standard	BCAA	Standard	BCAA	Standard
1) Ott 1988	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA
2) Von Meyenfeldt 1990	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA
3) Van Way 1995	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA
4) Garcia De Lorenzo 1997	(A) ICU 18.5	(B) 14.4	(C) 17.8	NA	NA	NA	NA	NA
5) Kuhl 1990	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA	BCAA NA	Standard NA

C. Random: concealed randomization
 ITT: intent to treat
 BCAA: Branched chain amino acids
 AA: amino acids

NA: not available
 ** RR= relative risk, CI= Confidence intervals
 ‡ number of patients with infections unless specified

Review: Branched Chain Amino Acids
 Comparison: 01 High BCAA vs. Standard
 Outcome: 01 Mortality



TOPIC: 9.1 Composition of PN: Branched Chain Amino Acids

(Reviewers: Ulrich Suchner, Minto Jain, Brian Jurewitsch, Jim Kutsogiannis)

Article inclusion log

Criteria for study selection

Type of study: RCT or Meta-analysis
Population: critically ill, ventilated patients (no elective surgery patients)
Intervention: TPN and /or EN
Outcomes: mortality, LOS, QOL, functional recovery, complications, cost. Exclude studies with only biochemical, metabolic or nutritional outcomes.

	Author	Journal	I	E	why rejected
1.	Garcia De Lorenzo	CCMedicine 1997	√		
2.	Von Meyenfeldt	Br J Surgery 1990	√		
3.	Van Way	Am Surgeon 1985	√		
4.	Ott	Drug Intell Clin Pharm 1988	√		
5.	Kuhl	Surgery 1990	√		
6.	Jiminez	JPEN 1991		√	pseudorandomized
7.	Bower	Annals Surgery 1986		√	No significant outcomes
8.	Cerra	CCMedicine 1983		√	No significant outcomes
9.	Vanderwoude	CCMedicine 1986		√	No RCT, no significant outcomes
10.	Iapichino	Clinical Nutrition '85		√	No significant outcomes
11.	Chiarla	J Trauma 1988		√	No significant outcomes
12.	Naylor	Gastroenterology 1989		√	Not ICU patients

I = included, E = excluded

References

1. Garcia-de-Lorenzo A, Ortiz-Leyba C, Planas M, Montejo JC, Nunez R, Ordonez FJ, Aragon C, Jimenez FJ. Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects. *Crit Care Med.* 1997 Mar; 25(3): 418-24.
2. von Meyenfeldt MF, Soeters PB, Vente JP, van Berlo CL, Rouflart MM, de Jong KP, van der Linden CJ, Gouma DJ. Effect of branched chain amino acid enrichment of total parenteral nutrition on nitrogen sparing and clinical outcome of sepsis and trauma: a prospective randomized double blind trial. *Br J Surg.* 1990 Aug; 77(8): 924-9.
3. Van Way CW 3rd, Moore EE, Allo M, Solomons C, Gordon S, Jones T. Comparison of total parenteral nutrition with 25 per cent and 45 per cent branched chain amino acids in stressed patients. *Am Surg.* 1985 Nov; 51(11): 609-16.
4. Ott LG, Schmidt JJ, Young AB, Twyman DL, Rapp RP, Tibbs PA, Dempsey RJ, McClain CJ. Comparison of administration of two standard intravenous amino acid formulas to severely brain-injured patients. *Drug Intell Clin Pharm.* 1988 Oct; 22(10): 763-8.
5. Kuhl DA, Brown RO, Vehe KL, Boucher BA, Luther RW, Kudsk KA. Use of selected visceral protein measurements in the comparison of branched-chain amino acids with standard amino acids in parenteral nutrition support of injured patients. *Surgery.* 1990 May; 107(5): 503-10.
6. Bower RH, Muggia-Sullam M, Vallgren S, Hurst JM, Kern KA, LaFrance R, Fischer JE. Branched chain amino acid-enriched solutions in the septic patient. A randomized, prospective trial. *Ann Surg.* 1986 Jan; 203(1): 13-20.
7. Cerra FB, Mazuski J, Teasley K, Nuwer N, Lysne J, Shronts E, Konstantinides F. Nitrogen retention in critically ill patients is proportional to the branched chain amino acid load. *Crit Care Med.* 1983 Oct; 11(10): 775-8.
8. Chiarla C, Siegel JH, Kidd S, Coleman B, Mora R, Tacchino R, Placko R, Gum M, Wiles CE 3rd, Belzberg H, et al. Inhibition of post-traumatic septic proteolysis and ureagenesis and stimulation of hepatic acute-phase protein production by branched-chain amino acid TPN. *J Trauma.* 1988 Aug; 28(8): 1145-72.
9. Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. *Gastroenterology.* 1989 Oct; 97(4): 1033-42

10. Jiminez Jiminez JJ, et al. Prospective study on the efficacy of branched chain amino acids in septic patients. JPEN: 15(13):252 1991.